Definium Therapeutics Stock Analysis
| DFTX Stock | 16.25 0.78 4.58% |
IPO Date 11th of July 2022 |
At this time, Definium Therapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Interest Debt Per Share is likely to rise to 0.32 in 2026, whereas Net Debt is likely to drop (238 M) in 2026. With a high degree of financial leverage come high-interest payments, which usually reduce Definium Therapeutics' Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0651 | Current Value 0.038 | Quarterly Volatility 0.03346106 |
Definium Therapeutics is overvalued with Real Value of 12.94 and Hype Value of 16.47. The main objective of Definium Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Definium Therapeutics is worth, separate from its market price. There are two main types of Definium Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Definium Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Definium Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Definium Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Definium Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. Definium Stock Analysis Notes
The company had not issued any dividends in recent years. To learn more about Definium Therapeutics call Robert Barrow at 212 220 6633 or check out https://definiumtx.com.Definium Therapeutics Investment Alerts
| Definium Therapeutics appears to be risky and price may revert if volatility continues | |
| Definium Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Definium Therapeutics was previously known as Mind Medicine and was traded on NASDAQ Exchange under the symbol MNMD. | |
| Net Loss for the year was (108.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Definium Therapeutics generates negative cash flow from operations | |
| Definium Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from simplywall.st: Is Adsetts Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics |
Definium Largest EPS Surprises
Earnings surprises can significantly impact Definium Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.33 | -0.26 | 0.07 | 21 | ||
2025-03-06 | 2024-12-31 | -0.31 | -0.41 | -0.1 | 32 | ||
2024-11-07 | 2024-09-30 | -0.28 | -0.18 | 0.1 | 35 |
Definium Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.52) | (0.54) |
Technical Drivers
As of the 7th of February, Definium Therapeutics shows the Mean Deviation of 3.23, coefficient of variation of 1435.95, and Downside Deviation of 3.79. Definium Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Definium Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Definium Therapeutics Predictive Daily Indicators
Definium Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Definium Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Definium Therapeutics Corporate Filings
F4 | 5th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 29th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of October 2025 Other Reports | ViewVerify | |
| 29th of October 2025 Other Reports | ViewVerify |
Definium Therapeutics Forecast Models
Definium Therapeutics' time-series forecasting models are one of many Definium Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Definium Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Definium Therapeutics Financial Rating
Definium Therapeutics financial ratings play a critical role in determining how much Definium Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Definium Therapeutics' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (5.98) | Unlikely Manipulator | View |
Definium Therapeutics Total Assets Over Time
Definium Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Definium Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Definium Therapeutics Debt Ratio | 3.8 |
Definium Net Debt
About Definium Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Definium Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Definium shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Definium Therapeutics. By using and applying Definium Stock analysis, traders can create a robust methodology for identifying Definium entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Definium Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.